Molecular Formula | C15H22N2O2 |
Molar Mass | 262.35 |
Density | 1.150±0.06 g/cm3(Predicted) |
Boling Point | 437.3±35.0 °C(Predicted) |
Solubility | DMSO: soluble10mg/mL, clear |
Appearance | Morphological powder |
Color | faint purple to brown |
pKa | 4.78±0.11(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. |
Physical and Chemical Properties | Bioactive Ferrostatin-1 (Fer-1) is an effective selective ferroptosis inhibitor with EC50 of 60 nM. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
Hazard Class | IRRITANT |
Raw Materials | 4-(cyclohexylamino)-3-nitro-benzoic acid ethyl ester |
Reference Show more | 1. [IF=11.556] Junjie Ren et al."Ultrasound (US)-activated redox dyshomeostasis therapy reinforced by immunogenic cell death (ICD) through a mitochondrial targeting liposomal nanosystem."Theranostics. 2021; 11(19): 9470–9491 2. [IF=8.183] Zhicheng Zhang et al."Versatile iron-vitamin K 3 derivative-based nanoscale coordination polymer augments tumor ferroptotic therapy."Nano Res. 2021 Jul;14(7):2398-2409 3. [IF=3.59] Jie Zhao et al."Activation of SSAT1/ALOX15 Axis Aggravates Cerebral Ischemia/Reperfusion Injury via Triggering Neuronal Ferroptosis."Neuroscience. 2022 Mar;485:78 4. [IF=6.313] Yijia Yang et al."Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin."Antioxidants-Basel. 2022 Apr;11(4):710 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.812 ml | 19.059 ml | 38.117 ml |
5 mM | 0.762 ml | 3.812 ml | 7.623 ml |
10 mM | 0.381 ml | 1.906 ml | 3.812 ml |
5 mM | 0.076 ml | 0.381 ml | 0.762 ml |
Target
Target Value
Ferroptosis
(HT-1080 cells) 60 nM(EC50)
in vitro studies
Ferrostatin-1(2 μM) acts on cancer cells and inhibits Erastin-induced Ferroptosis. Ferroptosis is an iron-dependent non-apoptotic cell death. it Ferrostatin-1 acts on neonatal rat brain slices and inhibits glutamate-induced cell death. Ferrostatin-1 is a lipid ROS scavenger with an N-cyclohexyl moiety that acts as a lipophilic anchor within the biofilm. Ferrostatin-1 does not inhibit extracellular signal-regulated kinase (ERK) phosphorylation or HT-1080 cell proliferation arrest, indicating that Ferrostatin-1 does not inhibit MEK/ERK pathway, chelated iron, or inhibit protein synthesis. Ferrostatin-1 inhibits Erastin-induced cytosolic and lipid ROS accumulation. Under the condition of cell-free, the Ferrostatin-1 is easy to oxidize and stabilize the free radical 2, 2-diphenyl-1-picrohydrazinyl (DPPH).
In vivo studies
Ferrostatin-1 inhibits cell death in cellular models of Huntington's disease (HD), periventricular leukomalacia (PVL), and kidney dysfunction .
Ferrostatin-1 (0.8 mg/kg; tail vein injection) effectively alleviated LPS-induced induced acute lung injury (ALI).
Ferrostatin-1 (I .p.; 5 mg/kg; C57BL/6J mice) improves renal function in mice with rhabdomyolysis.
Animal Model: Male C57BL/6 mice (LPS-induced ALI)
Dosage: 0.8 mg/kg
Administration: Tail vein injection
Result: Exerted therapeutic action against LPS-induced ALI.